EF Hutton initiates coverage on ImmunityBio Inc. (IBRX) with a Buy rating and a $30 price target, citing the potential of its Anktiva drug to revolutionize cancer immunotherapy. Anktiva has shown promising results in treating BCG-unresponsive non-muscle invasive bladder cancer and has also demonstrated the ability to enhance the effectiveness of checkpoint inhibitors in advanced non-small cell lung cancer.